Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Table 4 Results of this analysis

Outcomes which were assessed	OR with 95% CI	P value	I² (%)
Composite endpoint	0.81 [0.74–0.88]	0.00001	19
All-cause mortality	0.82 [0.72–0.92]	0.0009	0
Cardiac death	0.80 [0.69–0.92]	0.002	0
Myocardial infarction	0.87 [0.77–0.98]	0.03	10
Stent thrombosis	0.73 [0.55–0.97]	0.03	28
Stroke	0.77 [0.43–1.38]	0.38	81
TIMI defined minor bleeding	2.27 [1.47–3.49]	0.0002	0
TIMI defined major bleeding	3.44 [1.13–10.52]	0.03	74
Intracranial bleeding	1.63 [1.04–2.56]	0.03	44
Fatal bleeding	1.19 [0.74–1.91]	0.48	0
ISTH bleeding	1.80 [1.45–2.22]	0.00001	0

TIMI thrombolysis in myocardial infarction, ISTH International Society on Thrombosis and Hemostasis, OR odds ratios, CI confidence intervals

ISSN: 2050-6511